Search

Displaying results 2201 - 2210 of 8412 in total
  1. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential appl...

  2. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

  3. Drug

    Aluminum oxide

    go.drugbank.com/drugs/DB11342
    ApprovedWithdrawn

    It is considered an indirect additive used in food contact substances by the FDA.

    Mixtures: POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOS
  4. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    Velmanase alfa has an amino acid sequence of the monomeric protein identical to the naturally occurring human alpha-mannosidase. … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.

  5. Drug

    Oxitriptan

    go.drugbank.com/drugs/DB02959
    ApprovedInvestigationalNutraceuticalWithdrawn

    occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an

  6. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.

  7. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

  9. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  10. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.